David Varner, an international marketing specialist, has joined Bioventus, as Vice President of Marketing, Active Healing Therapies (AHT).
David Varner New VP Marketing for AHT at Bioventus

“We are very pleased David is joining us to lead global marketing for our Active Healing Therapies business [AHT],” said Bioventus Chief Commercial Officer John Nosenzo in the April 24, 2017 news release. “His deep experience in healthcare sales, marketing and operations roles combined with his ability to create high performing teams and launch new initiatives will help Bioventus continue to develop our AHT product portfolio and accelerate our growth in orthobiologics around the world.”
According to the company, Varner, who holds a Bachelor of Arts from The College of William and Mary, will be responsible for developing and executing global strategic marketing plans for the AHT business. He will also provide leadership to its sales training, marketing intelligence, marketing, external communications and professional affairs & medical education business functions.
“Varner joins Bioventus from Beckman Coulter Diagnostics, where he served as Vice President, Global Sales Operations,” states the news release. “Previously he worked in the Life Sciences Division of GE Healthcare in a succession of marketing and sales leadership positions, last serving as the company’s General Manager, Global Marketing Operations. Prior to that, Varner spent 13 years in a variety of sales, marketing and operations roles with Siemens Medical Diagnostics (formerly Bayer Diagnostics).”
Varner told OTW, “Our goal is to be with customers and the sales organization to understand their needs, challenges and what we can do to be their partner of choice. The landscape continues to evolve and we need to ensure that we are proactive in exceeding customer’s expectations. In the end, it is and should always be about the patient.”
“One year from now our journey should have us at a place where we are delivering quality products and services to our customers. We have a clear working knowledge of the market needs and that our efforts to support the sales force align with customer expectations. The goal is to begin to look around the corner and proactively anticipate the market needs.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.